Reviewed by Michael Gill, B. Sc.
25 Peritoneal Carcinomatosis Clinical Trials Near Me
Top Hospitals for Peritoneal Carcinomatosis Clinical Trials
Image of M D Anderson Cancer Center in Texas.
M D Anderson Cancer Center
10Active Trials
24All Time Trials for Peritoneal Carcinomatosis
2005First Peritoneal Carcinomatosis Trial
Image of National Institutes of Health Clinical Center in Maryland.
National Institutes of Health Clinical Center
4Active Trials
6All Time Trials for Peritoneal Carcinomatosis
2005First Peritoneal Carcinomatosis Trial
Top Cities for Peritoneal Carcinomatosis Clinical Trials
Peritoneal Carcinomatosis Clinical Trials by Phase of Trial
Phase < 1 Peritoneal Carcinomatosis Clinical Trials
7Active Peritoneal Carcinomatosis Clinical Trials
7Number of Unique Treatments
13Number of Active Locations
Most Recent Peritoneal Carcinomatosis Clinical Trials
Top Treatments for Peritoneal Carcinomatosis Clinical Trials
Treatment Name
Active Peritoneal Carcinomatosis Clinical Trials
All Time Trials for Peritoneal Carcinomatosis
First Recorded Peritoneal Carcinomatosis Trial
Quality-of-Life Assessment
Recently Completed Studies with FDA Approved Treatments for Peritoneal Carcinomatosis
Talimogene Laherparepvec
Dan Blazer III, M.D.
Hoffmann-La Roche
University of Massachusetts, Worcester

What are Peritoneal Carcinomatosis Clinical Trials?

Peritoneal carcinomatosis (PC) is a rare cancer affecting the peritoneum, the thin membrane enveloping the abdominal organs. There are two types of PC: primary and secondary.

Primary peritoneal carcinomatosis (PPC) is seen in women at a higher risk for ovarian cancer. The reason for this is unknown and recent research shows that women can still develop PPC after their ovaries have been removed. In 75% of cases of ovarian cancer, peritoneal carcinomatosis is seen.

Secondary peritoneal carcinomatosis develops as other abdominal growths spread to the peritoneum, leading to new growths. Due to this, PC is generally considered a sign of advanced abdominal cancer. There are no symptoms for the early stages of PC, but some cases have reported general symptoms such as diarrhea, constipation, bloating and frequent urination, which often leads to misdiagnosis.

Without treatment, survival is 4 – 7 months, while palliative care can increase the time to 12 – 23 months.

Why Is Peritoneal Carcinomatosis Being Studied Through Clinical Trials?

Peritoneal carcinomatosis (PC) is asymptomatic in its early stages, making it very challenging to detect and study. Estimates suggest it develops in 1 in every 3,300,000. In the cases of primary peritoneal carcinomatosis (PPC), researchers believe that as many as 15% of women diagnosed with ovarian cancer actually have PPC.

Clinical trials are essential to developing better early detection methods before the peritoneum has been wholly affected in both primary and secondary cases. As peritoneal carcinomatosis is linked to other cancers that develop in the abdominal cavity, its treatment is closely linked to cancer treatment trials.

What Treatment is Available for Peritoneal Carcinomatosis?

Peritoneal carcinomatosis (PC) can be confirmed in several ways. Blood tests and biopsies measure the amounts of particular antibody markers that signal cancerous growth. CT scans and MRIs are also done. These scans show the otherwise smooth peritoneum as grainy and bumpy.

As peritoneal carcinomatosis is often diagnosed during the late stages of other abdominal cancers, it is tough to treat. PC is unresponsive to chemotherapy, so most doctors focus on managing symptoms and pain instead.

However, if PC is detected earlier, a few treatment options are available, and they are commonly done together.

  • Cytoreductive surgery: Visible tumors growing on the peritoneum are removed along with adjacent abdominal organs if required.
  • Hyperthermic intraperitoneal chemotherapy (HIPEC): Chemotherapy medications are heated to 107 degrees Fahrenheit. The abdominal cavity is bathed in these heated drugs to kill any cancer cells left behind in the abdomen.
  • Peritonectomy: A surgery that removes the peritoneum lining. It is done with cytoreductive surgery.

What are Some Recent Peritoneal Carcinomatosis Clinical Trial Breakthroughs?

2009: This study suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) can help increase the 5-year survival rate from 15% to 50%. More research is necessary to verify these results.

2016: This study suggests that patients who have had a salpingo-oophorectomy or oophorectomy can still develop primary peritoneal carcinomatosis (PPC), concluding that follow-ups and long-term healthcare are necessary to prevent the development of PPC.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020 Jun 30;48(3):1101-1108. doi: 10.1042/BST20191092. Review. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1;28(1):63-8. doi: 10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Apr 1;28(10):1808. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr;17(3):206-25. doi: 10.1111/j.1549-8719.2010.00029.x. Review. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Sep 11;371(11):1039-49. doi: 10.1056/NEJMra1404198. Review. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010 Sep;17(9):2370-7. doi: 10.1245/s10434-010-1039-7. Epub 2010 Mar 25. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Review. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr;17(3):206-25. doi: 10.1111/j.1549-8719.2010.00029.x. Review. Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol. 2013 Mar;Chapter 19:Unit19.7. doi: 10.1002/0471143030.cb1907s58.